Clinical trials: High-risk Breast Cancer
Breast Cancer, Radiation Toxicity
Intensity Modulated Radiotherapy With Concomitant Boost in Breast Cancer
To assess feasibility of postoperative IMRT with concomitant boost in moderate-high risk breast cancer in terms of late toxicity and local control
- Trial name
- NCT03471741
- Testing
- IMRT with concomitant boost, 3D-RT with sequential boost
- Volunteers
- 451 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Mammary Cancer
Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)
This is a prospective, single arm, open-label, exploratory study in women with primary operable HER2-positive, HER2-enriched(HER2-E)/ERBB2-high breast cancer according to PAM50 intrinsic subtype and a ERBB2 pre-defined cutoff…
- Trial name
- ELPIS (NCT04301375)
- Testing
- Pertuzumab and trastuzumab FDC subcutaneous, Paclitaxel, TDM1
- Where
- Spain
- Volunteers
- 27 people
- Sponsor
- David Garcia Cinca
Breast Cancer
S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be effective in preventing breast cancer.
- Trial name
- NCT00088972
- Testing
- celecoxib
- Where
- 9 sites in United States
- Volunteers
- 8 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer
To assess the role of interstitial brachytherapy alone compared to whole breast irradiation in a defined low-risk group of invasive breast cancer or ductal carcinoma in situ concerning local failure (all ipsilateral local…
- Trial name
- NCT00402519
- Testing
- Accelerated partial breast irradiation, External beam whole breast irradiation
- Where
- 11 sites in Austria, Germany and 3 more
- Volunteers
- 1,300 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Breast Cancer
PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial
Breast cancer is an optimal "model disease" for studying personalized medicine. Breast cancer was the first malignancy for which a predictive factor forecasting response to therapy was identified nearly 50 years ago; the…
- Trial name
- PETREMAC (NCT02624973)
- Testing
- Neoadjuvant tamoxifen + goserelin (premenopausal women), Neoadjuvant letrozole (postmenopausal women), Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)
- Where
- 7 sites in Norway
- Volunteers
- 200 people
- Sponsor
- Haukeland University Hospital
Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC)
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors.
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer
- Trial name
- NCT07557225
- Testing
- 18F-T2 PET/CT
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Breast Cancer
Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with QS21 may cause a stronger immune response and kill more tumor cells.
- Trial name
- NCT00470574
- Testing
- QS21, sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine, immunoenzyme technique
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Reconstruction, Perfusion; Complications
Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon
The purpose of the study is to determine whether pharmacologic delay using minoxidil in patients undergoing bilateral risk reducing mastectomy with reconstruction could achieve improvement in flap perfusion and flap viability at…
- Conditions
- Breast Reconstruction, Perfusion; Complications, High Risk for Breast Cancer, Genetic Predisposition
- Trial name
- NCT07264790
- Testing
- Minoxidil, Hair mousse
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Duke University
ER+ Breast Cancer, Breast Cancer
Evaluation of Adherence to Cell Cycle Inhibitors Used as Adjuvant Therapy in Patients With Localized Breast Cancer at High Risk of Recurrence.
Hormone receptor-positive (HR+) breast cancers represent the most common histological subtype of breast cancer, accounting for approximately 75% of cases, regardless of HER2 (human epidermal growth factor receptor 2) status (1).
- Conditions
- ER+ Breast Cancer, Breast Cancer, Early Breast Cancer, Endocrine Therapy
- Trial name
- AdheRA (NCT07443774)
- Where
- France
- Volunteers
- 81 people
- Sponsor
- University Hospital, Grenoble
Breast Cancer
Adherence to Intensive Surveillance for Hereditary Breast Cancer
Women with strong family histories of breast cancer are at increased risk to have breast cancer. Women whose close relatives have had breast cancer often have more breast cancer screening than other women their age.
- Trial name
- NCT00582803
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation or bone marrow transplantation may allow the…
- Trial name
- NCT00008203
- Testing
- aldesleukin, recombinant interferon gamma, carboplatin
- Where
- United States
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Breast Neoplasms
Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer
This study aims to examine whether estradiol is an appropriate for future Phase 3 studies as second or third line endocrine treatment.
- Trial name
- NCT00324259
- Testing
- Estradiol
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Washington University School of Medicine
Breast Cancer, Breast Neoplasm Female
High-intensity Exercise After Treatment
This pilot study tests the feasibility and preliminary efficacy of an 8-week, 3-arm pilot exercise trial in which 45 breast cancer survivors will be randomized to high-intensity interval training (HIIT; n=15), moderate-intensity…
- Trial name
- HEAT (NCT04950010)
- Testing
- High-Intensity Interval Training, Moderate-Intensity Exercise
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Nebraska
Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes
A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
This study tests a new treatment approach for people with early-stage triple negative breast cancer whose tumors have a high number of immune cells, called tumor-infiltrating lymphocytes or TILs, as seen by a pathologist on…
- Trial name
- NeoTILs (NCT07743190)
- Testing
- Carboplatin, Paclitaxcel, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Medical University of South Carolina
Breast Cancer
Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy
This is a Phase III, randomised, assessor-blind, parallel group, multicentre trial. At least 180 adult subjects with high-risk Stage II or Stage III / IV breast cancer will be randomised (1:1) to receive either Eurofarma's…
- Trial name
- NCT02768714
- Testing
- Eurofarma's pegfilgrastim, Neulastim
- Sponsor
- Eurofarma Laboratorios S.A.
Breast Cancer
Study of Moderate Dose Omega 3 Fatty Acid Supplement in Premenopausal Women at High Risk for Breast Cancer
This pilot study is an investigation of feasibility of moderate dose omega-3 fatty acid supplementation in pre-menopausal women at high risk for breast cancer who are considering future pregnancy.
- Trial name
- NCT03383835
- Testing
- Omega-3 Supplementation
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Lauren Nye
Breast Cancer, Triple Negative Breast Cancer
Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment
In this randomized, controlled, prospective, two-arm intervention study, the investigators plan to investigate the effects of high-intensity interval training in women diagnosed with triple-negative breast cancer.
- Trial name
- NCT06497322
- Testing
- Exercise intervention - High intensity interval training on a cycle-ergometer
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital of Cologne
Breast Fibroadenoma
Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)
Demonstrate the efficacy of High Intensity Focused Ultrasound in the treatment of the breast fibroadenoma.
- Trial name
- NCT01331954
- Testing
- Ultrasonic ablation device
- Where
- Bulgaria
- Volunteers
- 20 people
- Sponsor
- Theraclion
Breast Cancer Female
Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC
Patients with breast cancer, who have completed first line therapy (e.g., radiotherapy, chemotherapy, surgery), and who have to be identified with having a high risk of recurrence of cancer, will be eligible for the study.
- Trial name
- ADAPTlate (NCT04565054)
- Testing
- Abemaciclib 50 MG; 150mg 1-0-1 per os
- Where
- 85 sites in Germany, Poland and 1 more
- Volunteers
- 1,260 people
- Sponsor
- Women's Cancer Study Group GmbH
Breast Cancer
Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may kill more tumor cells.
- Trial name
- NCT00002680
- Testing
- filgrastim, cyclophosphamide, megestrol acetate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Yale University